A Phase I/II Trial of CCI-779 and Bevacizumab in Stage IV Renal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 18 Nov 2015
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 13 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Apr 2014 Planned End Date changed from 1 Jan 2100 to 1 Jan 2010.
- 20 Jul 2012 Planned end date changed from 1 Apr 2007 to 1 Jan 2100 as reported by ClinicalTrials.gov.